(Q46486799)

22 December 2017

title

Folinic acid administration following MTX as prophylaxis for GVHD in allogeneic HSCT centres in Australia and New Zealand (English)

1 reference

22 December 2017

0 references

0 references

D Bhurani

1

1 reference

22 December 2017

M Schifter

series ordinal

2

1 reference

22 December 2017

I Kerridge

series ordinal

3

1 reference

22 December 2017

language of work or name

English

0 references

publication date

14 July 2008

1 reference

22 December 2017

Bone Marrow Transplantation

published in

1 reference

22 December 2017

volume

42

1 reference

22 December 2017

issue

8

1 reference

22 December 2017

page(s)

547-550

1 reference

22 December 2017

In vivo binding of [3H]nimodipine in rat brain after transient forebrain ischemia

cites work

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.197

Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.197

Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.197

7 January 2021

Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.197

7 January 2021

Mucosal damage: a major risk factor for severe complications after cytotoxic therapy

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.197

7 January 2021

Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: an overview

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.197

7 January 2021

Mucositis in patients with hematologic malignancies: an overview.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.197

7 January 2021

Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.197

7 January 2021

Omission of day +11 methotrexate after allogeneic bone marrow transplantation is associated with increased risk of severe acute graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.197

7 January 2021

Folate supplementation during methotrexate therapy for patients with psoriasis

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.197

7 January 2021

Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.197

7 January 2021

Defining the appropriate dosage of folinic acid after high-dose methotrexate for childhood acute lymphatic leukemia that will prevent neurotoxicity without rescuing malignant cells in the central nervous system

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.197

7 January 2021

Folic acid supplementation during methotrexate immunosuppression is not associated with early toxicity, risk of acute graft-versus-host disease or relapse following hematopoietic transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.197

7 January 2021

Cyclosporin A versus methotrexate, followed by rescue with folinic acid as prophylaxis of acute graft-versus-host disease after bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.197

7 January 2021

A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow, Transplantation (EBMT). Chronic Leukaemia Working Party of the EBMT

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.197

7 January 2021

Statement of current majority practices in graft-versus-host disease prophylaxis and treatment in children.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.197

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.197

7 January 2021

Clinical assessment scale for the rating of oral mucosal changes associated with bone marrow transplantation. Development of an oral mucositis index

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.197

7 January 2021

Analysis of factors that correlate with mucositis in recipients of autologous and allogeneic stem-cell transplants

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.197

7 January 2021

Recombinant human keratinocyte growth factor palifermin reduces oral mucositis and improves patient outcomes after stem cell transplant

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.197

7 January 2021

Palifermin for oral mucositis after intensive therapy for hematologic cancers

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.197

7 January 2021

Identifiers

DOI

10.1038/BMT.2008.197

1 reference

22 December 2017

1 reference

22 December 2017